AstraZeneca Announces FDA Approval for Fasenra with No New Safety Signals

AstraZeneca announces FDA approval for Fasenra, a treatment for asthma and eosinophilic granulomatosis with polyangiitis. The drug's effectiveness in pediatric patients 6-11 years old is extrapolated from clinical trials in adults and adolescents. No new safety signals were observed, and treatment with Fasenra was associated with reductions in blood basophils. The drug is not cleared renally and has limited data available for patients with creatinine clearance values less than 30 mL/min.